PMID- 27909580
OWN - NLM
STAT- MEDLINE
DCOM- 20170424
LR  - 20201209
IS  - 2047-2986 (Electronic)
IS  - 2047-2978 (Print)
IS  - 2047-2978 (Linking)
VI  - 6
IP  - 2
DP  - 2016 Dec
TI  - Burden of Neisseria meningitidis infections in China: a systematic review and 
      meta-analysis.
PG  - 020409
LID - 020409
AB  - BACKGROUND: Neisseria meningitidis is a leading cause of bacterial meningitis and 
      septicemia in children and young adults worldwide. The disease burden associated 
      with N. meningitidis infections has not been systematically assessed in China. 
      Therefore, we undertook this study to determine the burden of meningococcal 
      disease in China. METHOD: We performed a systematic review and meta-analysis of 
      articles on N. meningitidis incidence, carriage, seroprevalence and mortality 
      rates in China by searching the Chinese BioMedical Database (CBM), China National 
      Knowledge Infrastructure (CNKI), Wanfang database and PubMed for publications 
      from January 2005 to Aug 2015. RESULTS: In total, 50 articles were included in 
      our analysis. The overall incidence of meningococcal disease and associated 
      mortality were estimated to be 1.84 (95% confidence interval (CI) 0.91-3.37) per 
      100 000 persons per year and 0.33 (95% CI 0.12-0.86) per 100 000 persons per 
      year, respectively. N. meningitidis carriage rate among the healthy population 
      was estimated to be 2.7% (95% CI 2.0-3.5%). Prevalence of antibodies against N. 
      meningitidis serogroup A and C were estimated to be 77.3% (95% CI 72.4%-81.6%) 
      and 33.5% (95% CI 27.0%-40.8%), respectively. No studies were found for serogroup 
      specific disease burden. CONCLUSIONS: The overall incidence of meningococcal 
      disease in China is low. The lower seroprevalence of serogroup C within the 
      population suggests that it may pose a greater risk for meningococcal disease 
      outbreak than serogroup A. The lack of data on serogroup disease burden by age 
      groups suggests the implementation of laboratory based meningococcal surveillance 
      systems are urgently needed in China.
FAU - Zhang, Yaowen
AU  - Zhang Y
AD  - Infection Management and Disease Prevention Department, China-Japan Friendship 
      Hospital, Hepingli, Beijing, China.
FAU - Wei, Dong
AU  - Wei D
AD  - Infection Management and Disease Prevention Department, China-Japan Friendship 
      Hospital, Hepingli, Beijing, China.
FAU - Guo, Xinzhen
AU  - Guo X
AD  - Department of Infectious Diseases, China-Japan Friendship Hospital, Hepingli, 
      Beijing, China.
FAU - Han, Mai
AU  - Han M
AD  - Department of Infectious Diseases, China-Japan Friendship Hospital, Hepingli, 
      Beijing, China.
FAU - Yuan, Lichao
AU  - Yuan L
AD  - Department of Infectious Diseases, China-Japan Friendship Hospital, Hepingli, 
      Beijing, China.
FAU - Kyaw, Moe H
AU  - Kyaw MH
AD  - Sanofi Pasteur, Discovery Drive, Swiftwater, PA, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - Scotland
TA  - J Glob Health
JT  - Journal of global health
JID - 101578780
RN  - 0 (Antibodies)
SB  - IM
MH  - Antibodies/blood
MH  - China
MH  - Humans
MH  - Meningococcal Infections/*epidemiology/microbiology
MH  - *Neisseria meningitidis
MH  - *Serogroup
PMC - PMC5112005
EDAT- 2016/12/03 06:00
MHDA- 2017/04/25 06:00
PMCR- 2016/11/07
CRDT- 2016/12/03 06:00
PHST- 2016/12/03 06:00 [entrez]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2017/04/25 06:00 [medline]
PHST- 2016/11/07 00:00 [pmc-release]
AID - jogh-06-020409 [pii]
AID - 10.7189/jogh.06.020409 [doi]
PST - ppublish
SO  - J Glob Health. 2016 Dec;6(2):020409. doi: 10.7189/jogh.06.020409.